Application No.: 10/049,419

Art Unit 1623

Reply to Final Office Action Dated January 25, 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-32. (Cancelled)

33. (**Currently Amended**) A method of treating <u>an</u> autoimmune disease, anemia, diabetes, septic shock, inflammatory enteropathy, chronic articular rheumatism, multiple sclerosis, uveitis or an allergic disease, wherein the method comprises:

administering a fucoidan derived from *Kjellmaniella crassifolia* and/or a degradation product thereof to a subject in need thereof for treating said autoimmune disease, anemia, diabetes, septic shock, inflammatory enteropathy, chronic articular rheumatism, multiple sclerosis, uveitis or said allergic disease.

34-36. (**Cancelled**)

- 37. (**Previously Presented**) The method according to claim 33, wherein the disease is an allergic disease requiring suppression of IgE production.
- 38. (**Previously Presented**) The method according to claim 33, wherein the fucoidan and/or a degradation product thereof are orally administered.

2 MSW/ETP/las

Application No.: 10/049,419

Art Unit 1623

Reply to Final Office Action Dated January 25, 2005

39-60. (Cancelled)

61. (Previously Presented) The method according to claim 33, wherein a food, drink or

feed containing the fucoidan and/or a degradation product thereof as an effective ingredient is

used.

62. (Previously Presented) The method according to claim 33, wherein a cosmetic

containing the fucoidan and/or a degradation product thereof as an effective ingredient is used.

63. (Previously Presented) The method according to claim 62, wherein the cosmetic is

percutaneously administered.

3 MSW/ETP/las